Inogen (INGN) Cash from Investing Activities Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -253.01% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | -11.91% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -41.67% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -6.88% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -472.46% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | -16.93% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -111.03% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | -40.94% |
| 10 | Inogen | 165.85 Mn | 71.44 Mn | 37.86 Mn | 51.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 51.31% |
| Dec 31, 2025 | 39.79% |
| Sep 30, 2025 | 74.16% |
| Jun 30, 2025 | -87.87% |
| Mar 31, 2025 | 20.47% |
| Dec 31, 2024 | 43.13% |
| Sep 30, 2024 | -35.83% |
| Jun 30, 2024 | -41.07% |
| Mar 31, 2024 | -150.05% |
| Dec 31, 2023 | 30.51% |
| Sep 30, 2023 | -79.11% |
| Jun 30, 2023 | 59.36% |
| Mar 31, 2023 | -57.71% |
| Dec 31, 2022 | -30.47% |
| Sep 30, 2022 | 59.89% |
| Jun 30, 2022 | -1.60% |
| Mar 31, 2022 | 16.45% |
| Dec 31, 2021 | -101.56% |
| Sep 30, 2021 | 28.49% |
| Jun 30, 2021 | 27.27% |
| Mar 31, 2021 | 29.36% |
| Dec 31, 2020 | -82.62% |
| Sep 30, 2020 | -10.99% |
| Jun 30, 2020 | 11.97% |
| Mar 31, 2020 | 63.41% |
| Dec 31, 2019 | 289.71% |
| Sep 30, 2019 | -90.31% |
| Jun 30, 2019 | 72.56% |
| Mar 31, 2019 | -110.86% |
| Dec 31, 2018 | 83.73% |
| Sep 30, 2018 | -11.77% |
| Jun 30, 2018 | 13.93% |
| Mar 31, 2018 | -14.02% |
| Dec 31, 2017 | 14.57% |
| Sep 30, 2017 | -14.91% |
| Jun 30, 2017 | -39.91% |
| Mar 31, 2017 | -5.26% |
| Dec 31, 2016 | 46.76% |
| Sep 30, 2016 | -25.64% |
| Jun 30, 2016 | 33.48% |
| Mar 31, 2016 | 31.31% |